Antihistamines for Atopic Dermatitis

Atopic dermatitis (AD) is a complex inflammatory skin disease driven predominantly by type 2 inflammation. Although histamine is not considered a primary mediator of AD-associated pruritus, antihistamines continue to be used frequently for the treatment of itch in AD.¹ 

In a 2026 systematic review and network meta-analysis, Chu et al found that add-on oral antihistamines did not provide clinically meaningful improvement in AD severity or itch.² They also found that first-generation antihistamines may increase the risk of cognitive impairment. 

RESEARCH SUMMARY 

Chu et al performed a systematic review and random-effects Bayesian network meta-analysis of randomized trials assessing add-on H1 antihistamines, H2 blockers, mast cell stabilizers, and combinations of these therapies.² The researchers searched MEDLINE, Embase, CENTRAL, and United States and European regulatory databases through May 5, 2025. The review included 47 trials involving 6230 children and adults with AD. Outcomes assessed included disease severity, itch, sleep disturbance, quality of life, flares, cognitive impairment, treatment discontinuation, and serious adverse events. 

Compared with placebo, second-generation H1 antihistamines produced small improvements in disease severity (objective SCORAD [Scoring Atopic Dermatitis] mean difference, −1.87 [95% credible interval (CrI), −3.47 to −0.27]) and itch severity (mean difference, −0.89 [95% CrI, −1.41 to −0.37]).2 Although statistically significant, these improvements were well below the minimal important differences of 8.2 for disease severity and 3 for itch, indicating that the observed effects were unlikely to be clinically meaningful. First-generation H1 antihistamines showed no significant improvement in either disease severity (mean difference, +1.04 [95% CrI, −2.03 to 4.12]) or itch (mean difference, −0.28 [95% CrI, −0.98 to 0.42]). 

Because AD trials provided limited evidence regarding cognitive impairment, the Bayesian analysis incorporated indirect evidence from 132 randomized trials in chronic urticaria involving 14,853 participants, consistent with the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework.² First-generation antihistamines were associated with increased rates of cognitive impairment (odds ratio [OR], 3.24; 66 more cases per 1000 patients; 95% CrI, 0 to 231 more) and discontinuation due to adverse events (OR, 4.61; 29 more discontinuations per 1000 patients; 95% CrI, 1 to 131 more). Among second-generation agents, loratadine was not associated with increased cognitive impairment, whereas cetirizine and levocetirizine were associated with 17 and 16 additional cases per 1000, respectively. Neither first- nor second-generation antihistamines were associated with an increase in serious adverse events. 

CLINICAL IMPLICATIONS 

A major strength of this systematic review and meta-analysis is its distinction between statistical significance and clinical importance. Although second-generation H1 antihistamines produced statistically significant improvements in disease severity and itch, the magnitude of these effects fell well below established thresholds for clinically meaningful improvement. In contrast, first-generation antihistamines provided no significant improvement in AD outcomes and may carry a meaningful cognitive burden. Thus, statistically detectable benefit should not be conflated with clinically meaningful benefit. 

These findings do not support the routine use of antihistamines specifically for the treatment of AD-associated itch or disease severity, particularly when potential adverse effects are considered. 

These findings are consistent with our current understanding of AD pathophysiology, particularly the predominantly nonhistaminergic mechanisms underlying AD-associated pruritus. Blocking H1 receptors, therefore, does not adequately target the pathways driving itch and inflammation in AD. Antihistamines may still be appropriate for patients with concomitant histamine-mediated conditions, such as urticaria or allergic rhinitis; however, their use for these conditions should not be interpreted as treatment of the underlying AD. 

Similarly, although sedating antihistamines have historically been used at bedtime in patients with AD, sedation should not be conflated with treatment of the underlying pruritus.